Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 138 results found. Search for [ USFDA on coronavirus ]

Results 40 to 60 of 138
BusinessToday.In
New Delhi, August 17, 2020
COVID-19 fallout: Japan's economy contracts at record pace, GDP declines 27.8%Japan was hit by its biggest economic contraction on record in the second quarter as the coronavirus pandemic crushed consumption and exports, keeping policy makers under pressure for bolder action to prevent a deeper recession. The third straight quarter of declines knocked the size of real gross domestic product (GDP) to decade-low levels, wiping out the benefits brought by Prime Minister Shinzo Abe's \"Abenomics...


PTI
August 17, 2020
The US has been plagued by an inconsistent strategy for detecting the virus, thanks in part to persistent shortages and the use of a variety of different tests that have sometimes yielded unreliable results


BusinessToday.In
August 7, 2020
Stock Market News Highlights: HCL Tech, followed by HDFC twins, Infosys, Sun Pharma, ICICI Bank and Kotak Bank were among the top losers on Sensex today, while Asian Paints, UltraTech Cement, Bajaj Finserv, IndusInd Bank and TCS were among the gainers.


Rajeev Dubey
New Delhi, August 5, 2020
Top Indian and global CEOs and experts on why the future is bright


PB Jayakumar
July 29, 2020
Last week, the DCGI had cancelled the rapid diagnostic kit import licences of three firms and suspended that of 16 others saying the US drug regulator USFDA has removed the manufacturers from their list of coronavirus serology test kits, with directions that they should not be distributed


PTI
July 25, 2020
The three firms are Cadila Healthcare, MDAAC International and N W Overseas while the 16 companies include Transasia Bio-Medicals, Cosmic Scientific, Inbios India, S D Biosensor, Accurex Biomedicals, Biohouse Solutions and Trivitron Healthcare among others


BusinessToday.In
New Delhi, July 23, 2020
Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report


BusinessToday.In
July 20, 2020
Remdesivir is one of the few medicines believed to be effective in treating coronavirus patients. So far, it has secured approvals for emergency use from US FDA and conditional approval from the European Commission.


PTI
July 18, 2020
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Butalbital, Acetaminophen and Caffeine tabletsin strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement


PTI
July 15, 2020
Covifor is the first generic brand of Remdesivir, which is meant for treatment of COVID-19 patients that are adults and children, hospitalised with severe symptoms of the disease


BusinessToday.In
July 14, 2020
The World Health Organisation has stated that it won't be prudent to expect a perfect vaccine just yet. The warning comes on the back of a study by King's College, London that showed antibodies fighting COVID-19 in recovered patients began to wane away in three months


BusinessToday.In
July 14, 2020
Stock Market Highlights on July 14: IndusInd Bank, Bajaj Finserv, Axis Bank, Bajaj Finance, Maruti and SBI were among the other laggards. On the other hand, HCL Tech, Infosys, Nestle India, UltraTech Cement and ITC were the gainers.


BusinessToday.In
July 13, 2020
Last month, Cipla introduced Remdesivir under the brand name 'CIPREMI' after receiving approval from DCGI for \"restricted emergency use\" on adult and paediatric patients hospitalised with suspected or laboratory-confirmed COVID-19 infection


BusinessToday.In
July 6, 2020
Mylan has been licensed by Gilead for marketing the drug in 127 low- and middle-income countries, including India. The company will manufacture remdesivir at its injectables facilities in India


PTI
July 6, 2020
\"Having said so, we believe FY2021 will have more uncertainties than ever before. Consequently, our overall performance may be quite volatile,\" Dr Reddy's Laboratories said


PTI
June 28, 2020
As of March 31, 2020, the company has 99 cumulative filings pending for approval with the US Food and Drug Administration (USFDA), including two new drug approvals (NDAs), he added


Rupa Burman Roy
June 22, 2020
Reliance Industries, Bajaj Finserv, Bajaj Finance, Bajaj Auto, IndusInd Bank and ICICI Bank were among the top Sensex gainers. On the contrary, TCS, ONGC, M&M and Infosys were among the top laggards


BusinessToday.In
June 22, 2020
Stock Market LIVE Updates on June 19: Reliance Industries, Bajaj Finserv, Bajaj Finance, Bajaj Auto, IndusInd Bank and ICICI Bank were among the top gaines on Sensex pack. On the contrary, TCS, ONGC, M&M and Infosys were among the top laggards


BusinessToday.In
June 17, 2020
Stock Market LIVE Updates: PowerGrid, NTPC, SBI, UltraTech Cement, M&M, HDFC Bank and Kotak Bank were among the top losers on Sensex pack. On the contrary, Maruti, Tech Mahindra, Axis Bank and Infosys were among the gainers


PB Jayakumar
June 16, 2020
About six Indian companies like Cipla, Jubilant, Hetero, Syngene, Dr Reddy's and Zydus Cadila were licensed to make and distribute the drug in over 120 geographies


PAGES 3 OF 7  12345